García-Hevia, L.; Muñoz-Guerra, D.; Casafont, Í.; Morales-Angulo, C.; Ovejero, V.J.; Lobo, D.; Fanarraga, M.L.
Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer. Biomedicines 2022, 10, 732.
https://doi.org/10.3390/biomedicines10040732
AMA Style
García-Hevia L, Muñoz-Guerra D, Casafont Í, Morales-Angulo C, Ovejero VJ, Lobo D, Fanarraga ML.
Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer. Biomedicines. 2022; 10(4):732.
https://doi.org/10.3390/biomedicines10040732
Chicago/Turabian Style
García-Hevia, Lorena, Débora Muñoz-Guerra, Íñigo Casafont, Carmelo Morales-Angulo, Victor J. Ovejero, David Lobo, and Mónica L. Fanarraga.
2022. "Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer" Biomedicines 10, no. 4: 732.
https://doi.org/10.3390/biomedicines10040732
APA Style
García-Hevia, L., Muñoz-Guerra, D., Casafont, Í., Morales-Angulo, C., Ovejero, V. J., Lobo, D., & Fanarraga, M. L.
(2022). Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer. Biomedicines, 10(4), 732.
https://doi.org/10.3390/biomedicines10040732